JLK, First Domestic Success in Validating AI Analysis Solution for Stroke Perfusion Imaging

JLK, the first medical AI company to be listed (CEO Kim Dong-min), announced on the 17th that it has succeeded for the first time in Korea in proving the clinical performance of a brain perfusion imaging diagnostic AI solution in medical practice, in a paper comparing the performance of CT perfusion (CTP) AI solutions published on the 15th in the international medical journal Frontiers.

CTP is an essential test for deciding the treatment of cerebral infarction among stroke patients, of whom more than 15 million occur worldwide annually. It is crucial for visualizing brain injury areas and quantitative volume analysis, and is known to have played a decisive role in extending the golden time for cerebral infarction patients to 24 hours from symptom onset.

In particular, AI analysis technology for CTP had been dependent on proprietary solutions developed by American companies, but with the clinical performance verification of JLK’s JLK-CTP, an important turning point has been reached.

Professor Jurjuchu of Augusta University in the United States, who reviewed the paper, praised, “The JLK-CTP brain perfusion imaging solution developed purely with Korean technology will play an important role in saving the lives of cerebral infarction patients in medical settings worldwide.”

Led by Professor Kim Beom-jun of the Department of Neurology at Bundang Seoul National University Hospital, this study evaluated and compared the precision and concordance of JLK’s JLK-CTP AI diagnostic solution and the AI diagnostic solution of the American company Rapid AI in 327 ischemic stroke patients who underwent CTP within 24 hours of onset.

According to the paper, in the comparison of MRI-based cerebral infarction volume (ischemic core), considered the gold standard, the JLK-CTP solution showed very high precision and concordance, and demonstrated superior performance by predicting the core volume of cerebral infarction more accurately compared to the American Rapid AI solution.

JLK CEO Kim Dong-min said, “It is encouraging that our CTP AI solution has proven superior performance compared to the competitor Rapid AI solution in AI diagnosis using perfusion images within 24 hours,” adding, “We will advance CT perfusion image analysis and aim to gain an advantage in competition with the global stroke AI big three companies, including JLK, the American Rapid AI, and Viz AI.”

Professor Kim Beom-jun, the corresponding author of the paper, stated, “We are accelerating the discovery of the most suitable testing methods for domestic cerebral infarction patients using the excellently developed JLK-CTP,” and added, “We expect JLK’s various solutions to be widely utilized in determining standard stroke treatment methods.”